4
Changes in Ownership
Edgewise Therapeutics, Inc. Filed Acc 0001562180-24-008599
Chief Development Officer sold 29,709 shares at an average $29.69 ($881,915)
- Chief Development Officer acquired 29,709 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Semigran Marc · Chief Development Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-12-24 | Exercise or conversion : show line 1 in the form 10b5-1 | +29,709 | $8.94 | $265,598 | 36,425 | D |
| 2024-12-24 | Sale : show line 2 in the form 10b5-1 | −27,980 | $29.66 | $829,906 | 8,445 | D |
| 2024-12-24 | Sale : show line 3 in the form 10b5-1 | −1,729 | $30.08 | $52,009 | 6,716 | D |
| Open-market sales · 29,709 sh · avg $29.69 · $881,915 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-12-24 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) | −29,709 | 270,291 | D |
Loading xslF345X05/primarydocument.xml…